DNA Script Launches Early Access Program to Latest Advances in SYNTAX Platform and Enzymatic DNA Synthesis Technology


Program participants get early access to the next release of kits designed to print longer oligos and enable labeling with fluorophores, quenchers and biotin.

SOUTH SAN FRANCISCO, CA & PARIS, April 12, 2022–(BUSINESS WIRE)–DNA Script, a world leader in enzymatic DNA synthesis (EDS) for on-demand DNA, announced the launch of a new program for customers of its SYNTAX system, in which organizations benefit from early access to the latest advances in their EDS technology. Dubbed the DNA Writers Early Access Program, its members already include the London Biofoundry and the BASE facility at the University of Queensland (UQ), Australia.

Through the DNA Scriptors program, the company will accelerate application expansion for its SYNTAX system by providing users with ongoing opportunities to access products prior to full commercial launch. New features of the SYNTAX platform that will be available for early access include a new generation of kits that allow the printing of longer oligos, up to 80 nt in length, and the synthesis of probes labeled with biotin or fluorophores and extinguishers.

“We have multiple development teams working to improve all aspects of our SYNTAX platform, from new chemistries that increase oligo mass, length and quality and enable modifications, to new instrument designs and upgrades. upgrades that increase the plex,” said DNA Script CEO and co-founder Thomas Ybert. “Feedback from over 40 alpha and beta contributors was critical to the successful launch of the SYNTAX system in June 2021, and this DNA Scriptors program ensures we continue to innovate with our customers’ needs in mind.”

Members of DNA Scriptors use the SYNTAX platform in a range of molecular biology and genetics applications. Among them, the London Biofoundry, based at Imperial College London, supplies synthetic DNA to universities and industry in London, UK. “Our rapid response Covid-19 projects have already benefited from early access to modified oligos, produced rapidly in-house, and we now look forward to leveraging biotinylated and longer oligos in our NGS workflows and gene synthesis with our partners,” said Marko. Storch, Ph.D., synthetic biology and automation lead.

Located within the Australian Institute of Bioengineering and Nanotechnology (AIBN) at UQ, the BASE facility provides genetic material to advance Australian research and has a particular focus on the development of cancer and other vaccines. “DNA Script’s SYNTAX System allows us to rapidly synthesize DNA to our precise requirements, which is essential for manufacturing vaccines and mRNA-based therapies,” said Tim Mercer, Ph.D., Director of BASE and Assistant Professor at AIBN. “Being part of the DNA Writers Early Access Program provides access to this cutting-edge technology needed to accelerate the manufacture of mRNA vaccines. This access will enable rapid response to emerging infectious diseases and support the development of personalized cancer vaccines.

The SYNTAX platform is a paradigm shift that enables labs to produce DNA on demand, with the world’s first benchtop enzymatic DNA printer. The system is built around EDS, which synthesizes DNA oligos as nature does, making it a much simpler, faster, and greener process than older approaches based on phosphoramidite chemistry.

About DNA Scripting
Founded in 2014, DNA Script is a pioneering life science technology company developing a new, faster, more powerful and more versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to laboratories with the first benchtop enzyme synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life science research with innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220412005439/en/


Press contacts in the United States
Valerie Enes
[email protected]

Contact DNA Script
Joleen Rau
[email protected]
[email protected]

Press contact in Europe
Caroline Carmagnol
06 64 18 99 59
[email protected]


Comments are closed.